Novel RasGRF1-derived Tat-fused peptides inhibiting Ras-dependent proliferation and migration in mouse and human cancer cells

Biotechnology Advances

Volumn 30, Issue 1, 2012, Pages 233-243

  Sacco, Elena ^a   Metalli, David ^a   Spinelli, Michela ^a   Manzoni, Romilde ^a   Samalikova, Maria ^a   Grandori, Rita ^a   Morrione, Andrea ^b   Traversa, Silvio ^c   Alberghina, Lilia ^a   Vanoni, Marco ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c Bioindustry Park Silvano Fumero   (Italy)

Author keywords

Anticancer agents; Cell penetrating peptides; Drug delivery; Drug design; Peptide engineering; Ras inhibitors; Ras dependent transformation

Indexed keywords

ANTI-CANCER AGENTS; CELL-PENETRATING PEPTIDES; CLINICAL TARGETS; CRITICAL EVENTS; DOMINANT NEGATIVE; DRUG DESIGN; HUMAN BLADDER CANCER; HUMAN CANCER CELLS; HUMAN TUMORS; IN-VITRO; INHIBITORY ACTIVITY; INTRACELLULAR LEVELS; MAMMALIAN CELLS; MODEL COMPOUND; MOUSE-FIBROBLASTS; OVER-EXPRESSION; RAS-DEPENDENT TRANSFORMATION; SPECIFIC INHIBITORS; STRUCTURAL CONSTRAINTS; TAT PROTEIN; WILD TYPES;

CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; DISEASES; DRUG DELIVERY; FIBROBLASTS; GENES; MAMMALS;

PEPTIDES;

ANTINEOPLASTIC AGENT; GUANINE NUCLEOTIDE EXCHANGE FACTOR; HYBRID PROTEIN; PEPTIDE; PEPTIDE FRAGMENT; RAS PROTEIN; TAT PEPTIDE (47 57), HUMAN IMMUNODEFICIENCY VIRUS 1; TAT PEPTIDE (47-57), HUMAN IMMUNODEFICIENCY VIRUS 1; TRANSACTIVATOR PROTEIN;

BIOENGINEERING; CANCER; CYTOLOGY; DRUG; ENZYME ACTIVITY; INHIBITOR; MORPHOLOGY; PHENOTYPE; PROTEIN; TUMOR;

AMINO ACID SEQUENCE; ANIMAL; ARTICLE; CELL MOTION; CELL PROLIFERATION; CELL STRAIN 3T3; CHEMICAL STRUCTURE; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; MOUSE; PROTEIN ENGINEERING; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DRUG DELIVERY SYSTEMS; HUMANS; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NIH 3T3 CELLS; PEPTIDE FRAGMENTS; PEPTIDES; PROTEIN ENGINEERING; RAS PROTEINS; RAS-GRF1; RECOMBINANT FUSION PROTEINS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TRANSFECTION;

MAMMALIA;

EID: 84855746319     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2011.05.011     Document Type: Article

References (80)

1. Abou-Alfa G.K., Chapman P.B., Feilchenfeldt J., Brennan M.F., Capanu M., Gansukh B., et al. Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine. Am J Clin Oncol 2011, 34:321-325.
2. Adjei A.A. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001, 93:1062-1074.
3. Adjei A.A. K-ras as a target for lung cancer therapy. J Thorac Oncol 2008, 3:S160-S163.
4. Ahmadian M.R., Zor T., Vogt D., Kabsch W., Selinger Z., Wittinghofer A., et al. Guanosine triphosphatase stimulation of oncogenic Ras mutants. Proc Natl Acad Sci U S A 1999, 96:7065-7070.
5. Airoldi C., Palmioli A., D'Urzo A., Colombo S., Vanoni M., Martegani E., et al. Glucose-derived Ras pathway inhibitors: evidence of Ras-ligand binding and Ras-GEF (Cdc25) interaction inhibition. Chembiochem 2007, 8:1376-1379.
6. Aoki Y., Niihori T., Narumi Y., Kure S., Matsubara Y. The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders. Hum Mutat 2008, 29:992-1006.
7. Bernards A. GAPs galore! A survey of putative Ras superfamily GTPase activating proteins in man and Drosophila. Biochim Biophys Acta 2003, 1603:47-82.
8. Boriack-Sjodin P.A., Margarit S.M., Bar-Sagi D., Kuriyan J. The structural basis of the activation of Ras by Sos. Nature 1998, 394:337-343.
9. Bos J.L., Rehmann H., Wittinghofer A. GEFs and GAPs: critical elements in the control of small G proteins. Cell 2007, 129:865-877.
10. Bossù P., Vanoni M., Wanke V., Alberghina L., Cesaroni M.P., Tropea F., et al. A dominant negative RAS-specific guanine nucleotide exchange factor reverses neoplastic phenotype in K-ras transformed mouse fibroblasts. Oncogene 2000, 19:2147-2154.
11. Brummelkamp T.R., Bernards R., Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002, 2:243-247.
12. Bustinza-Linares E., Kurzrock R., Tsimberidou A.M. Salirasib in the treatment of pancreatic cancer. Future Oncol 2010, 6:885-891.
13. Caulin C., Nguyen T., Longley M.A., Zhou Z., Wang X.J., Roop D.R. Inducible activation of oncogenic K-ras results in tumor formation in the oral cavity. Cancer Res 2004, 64:5054-5058.
14. Chiaradonna F., Gaglio D., Vanoni M., Alberghina L. Expression of transforming K-Ras oncogene affects mitochondrial function and morphology in mouse fibroblasts. Biochim Biophys Acta 2006, 1757:1338-1356.
15. Chiaradonna F., Sacco E., Manzoni R., Giorgio M., Vanoni M., Alberghina L. Ras-dependent carbon metabolism and transformation in mouse fibroblasts. Oncogene 2006, 25:5391-5404.
16. Chin L., Tam A., Pomerantz J., Wong M., Holash J., Bardeesy N., et al. Essential role for oncogenic Ras in tumour maintenance. Nature 1999, 400:468-472.
17. Dekker F.J., Hedberg C. Small molecule inhibition of protein depalmitoylation as a new approach towards downregulation of oncogenic Ras signalling. Bioorg Med Chem 2010, 19:1376-1380.
18. DeNicola G.M., Tuveson D.A. RAS in cellular transformation and senescence. Eur J Cancer 2009, 45(Suppl 1):211-216.
19. Dietz G.P., Bahr M. Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol Cell Neurosci 2004, 27:85-131.
20. Di Fiore F., Sesboue R., Michel P., Sabourin J.C., Frebourg T. Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer. Br J Cancer 2010, 103:1765-1772.
21. Ducker C.E., Griffel L.K., Smith R.A., Keller S.N., Zhuang Y., Xia Z., et al. Discovery and characterization of inhibitors of human palmitoyl acyltransferases. Mol Cancer Ther 2006, 5:1647-1659.
22. Fonseca S.B., Pereira M.P., Kelley S.O. Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv Drug Deliv Rev 2009, 61:953-964.
23. Freedman T.S., Sondermann H., Friedland G.D., Kortemme T., Bar-Sagi D., Marqusee S., et al. A Ras-induced conformational switch in the Ras activator Son of sevenless. Proc Natl Acad Sci USA 2006, 103:16692-16697.
24. Freedman T.S., Sondermann H., Kuchment O., Friedland G.D., Kortemme T., Kuriyan J. Differences in flexibility underlie functional differences in the Ras activators son of sevenless and Ras guanine nucleotide releasing factor 1. Structure 2009, 17:41-53.
25. Geyer M., Schweins T., Herrmann C., Prisner T., Wittinghofer A., Kalbitzer H.R. Conformational transitions in p21ras and in its complexes with the effector protein Raf-RBD and the GTPase activating protein GAP. Biochemistry 1996, 35:10308-10320.
26. Geyer M., Herrmann C., Wohlgemuth S., Wittinghofer A., Kalbitzer H.R. Structure of the Ras-binding domain of RalGEF and implications for Ras binding and signalling. Nat Struct Biol 1997, 4:694-699.
27. Gronwald W., Huber F., Grunewald P., Sporner M., Wohlgemuth S., Herrmann C., et al. Solution structure of the Ras binding domain of the protein kinase Byr2 from Schizosaccharomyces pombe. Structure 2001, 9:1029-1041.
28. Hingorani S.R., Tuveson D.A. Ras redux: rethinking how and where Ras acts. Curr Opin Genet Dev 2003, 13:6-13.
29. Jeong S., Han S.R., Lee Y.J., Kim J.H., Lee S.W. Identification of RNA aptamer specific to mutant KRAS protein. Oligonucleotides 2010, 20:155-161.
30. Kalbitzer H.R., Spoerner M., Ganser P., Hozsa C., Kremer W. Fundamental link between folding states and functional states of proteins. J Am Chem Soc 2009, 131:16714-16719.
31. Karnoub A.E., Weinberg R.A. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 2008, 9:517-531.
32. Kilic U., Kilic E., Dietz G.P., Bahr M. The TAT protein transduction domain enhances the neuroprotective effect of glial-cell-line-derived neurotrophic factor after optic nerve transection. Neurodegener Dis 2004, 1:44-49.
33. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
34. Le Moulec S., Loriot Y., Soria J.C. Targeting KRAS pathway in NSCLC therapy. Bull Cancer 2009, 96(Suppl):S69-S74.
35. Lemoine N.R., Mayall E.S., Wyllie F.S., Williams E.D., Goyns M., Stringer B., et al. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 1989, 4:159-164.
36. Lenzen C., Cool R.H., Prinz H., Kuhlmann J., Wittinghofer A. Kinetic analysis by fluorescence of the interaction between Ras and the catalytic domain of the guanine nucleotide exchange factor Cdc25Mm. Biochemistry 1998, 37:7420-7430.
37. Leonard D.M. Ras farnesyltransferase: a new therapeutic target. J Med Chem 1997, 40:2971-2990.
38. Linnemann T., Geyer M., Jaitner B.K., Block C., Kalbitzer H.R., Wittinghofer A., et al. Thermodynamic and kinetic characterization of the interaction between the Ras binding domain of AF6 and members of the Ras subfamily. J Biol Chem 1999, 274:13556-13562.
39. Lovat F., Bitto A., Xu S.Q., Fassan M., Goldoni S., Metalli D., et al. Proepithelin is an autocrine growth factor for bladder cancer. Carcinogenesis 2009, 30:861-868.
40. Martegani E., Vanoni M., Zippel R., Coccetti P., Brambilla R., Ferrari C., et al. Cloning by functional complementation of a mouse cDNA encoding a homologue of CDC25, a Saccharomyces cerevisiae RAS activator. EMBO J 1992, 11:2151-2157.
41. Mesa R.A. Tipifarnib: farnesyl transferase inhibition at a crossroads. Expert Rev Anticancer Ther 2006, 6:313-319.
42. Metalli D., Lovat F., Tripodi F., Genua M., Xu S.Q., Spinelli M., et al. The insulin-like growth factor receptor I promotes motility and invasion of bladder cancer cells through Akt- and mitogen-activated protein kinase-dependent activation of paxillin. Am J Pathol 2010, 176:2997-3006.
43. Mitin N., Rossman K.L., Der C.J. Signaling interplay in Ras superfamily function. Curr Biol 2005, 15:R563-R574.
44. Morgillo F., Lee H.Y. Lonafarnib in cancer therapy. Expert Opin Investig Drugs 2006, 15:709-719.
45. Nazarian R., Shi H., Wang Q., Kong X., Koya R.C., Lee H., et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468:973-977.
46. Palmioli A., Sacco E., Abraham S., Thomas C.J., Di Domizio A., De Gioia L., et al. First experimental identification of Ras-inhibitor binding interface using a water-soluble Ras ligand. Bioorg Med Chem Lett 2009, 19:4217-4222.
47. Palmioli A., Sacco E., Airoldi C., Di Nicolantonio F., D'Urzo A., Shirasawa S., et al. Selective cytotoxicity of a bicyclic Ras inhibitor in cancer cells expressing K-Ras(G13D). Biochem Biophys Res Commun 2009, 386:593-597.
48. Pamonsinlapatham P., Hadj-Slimane R., Lepelletier Y., Allain B., Toccafondi M., Garbay C., et al. P120-Ras GTPase activating protein (RasGAP): a multi-interacting protein in downstream signaling. Biochimie 2009, 91:320-328.
49. Pasca di Magliano M., Sekine S., Ermilov A., Ferris J., Dlugosz A.A., Hebrok M. Hedgehog/Ras interactions regulate early stages of pancreatic cancer. Genes Dev 2006, 20:3161-3173.
50. Pulciani S., Santos E., Long L.K., Sorrentino V., Barbacid M. Ras gene amplification and malignant transformation. Mol Cell Biol 1985, 5:2836-2841.
51. Quilliam L.A., Rebhun J.F., Castro A.F. A growing family of guanine nucleotide exchange factors is responsible for activation of Ras-family GTPases. Prog Nucleic Acid Res Mol Biol 2002, 71:391-444.
52. Rizzo S., Bronte G., Fanale D., Corsini L., Silvestris N., Santini D., et al. Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?. Cancer Treat Rev 2010, 36(Suppl 3):S56-S61.
53. Roberts P.J., Der C.J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26:3291-3310.
54. Rodriguez-Viciana P., McCormick F. Characterization of interactions between ras family GTPases and their effectors. Methods Enzymol 2005, 407:187-194.
55. Rosnizeck I.C., Graf T., Spoerner M., Trankle J., Filchtinski D., Herrmann C., et al. Stabilizing a weak binding state for effectors in the human ras protein by cyclen complexes. Angew Chem Int Ed 2010, 49:3830-3833.
56. Sacco E., Fantinato S., Manzoni R., Metalli D., De Gioia L., Fantucci P., et al. The isolated catalytic hairpin of the Ras-specific guanine nucleotide exchange factor Cdc25Mm retains nucleotide dissociation activity but has impaired nucleotide exchange activity. FEBS Lett 2005, 579:6851-6858.
57. Sacco E., Metalli D., Busti S., Fantinato S., D'Urzo A., Mapelli V., et al. Catalytic competence of the Ras-GEF domain of hSos1 requires intra-REM domain interactions mediated by phenylalanine 577. FEBS Lett 2006, 580:6322-6328.
58. Sacco E., Abraham S., Palmioli A., Damore G., Bargna A., Mazzoleni E., et al. Binding properties and biological characterization of new sugar-derived Ras ligands. Med Chem Commun 2011, 2:396-401.
59. Sambrook J., Fritsch E.F., Maniatis T. Molecular cloning: a laboratory manual 1989, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. 2nd edn.
60. Schubbert S., Shannon K., Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev 2007, 7:295-308.
61. Sebbage V. Cell-penetrating peptides and their therapeutic applications. Biosci Hori 2009, 2:64-72.
62. Spoerner M., Herrmann C., Vetter I.R., Kalbitzer H.R., Wittinghofer A. Dynamic properties of the Ras switch I region and its importance for binding to effectors. Proc Natl Acad Sci USA 2001, 98:4944-4949.
63. Spoerner M., Wittinghofer A., Kalbitzer H.R. Perturbation of the conformational equilibria in Ras by selective mutations as studied by 31P NMR spectroscopy. FEBS Lett 2004, 578:305-310.
64. Spoerner M., Nuehs A., Ganser P., Herrmann C., Wittinghofer A., Kalbitzer H.R. Conformational states of Ras complexed with the GTP analogue GppNHp or GppCH2p: implications for the interaction with effector proteins. Biochemistry 2005, 44:2225-2236.
65. Spoerner M., Hozsa C., Poetzl J.A., Reiss K., Ganser P., Geyer M., et al. Conformational states of human rat sarcoma (Ras) protein complexed with its natural ligand GTP and their role for effector interaction and GTP hydrolysis. J Biol Chem 2010, 285:39768-39778.
66. Stathopoulos G.P., Androulakis N., Souglakos J., Stathopoulos J., Georgoulias V. Present treatment and future expectations in advanced pancreatic cancer. Anticancer Res 2008, 28:1303-1308.
67. Tanaka T., Rabbitts T.H. Interfering with RAS-effector protein interactions prevent RAS-dependent tumour initiation and causes stop-start control of cancer growth. Oncogene 2010, 29:6064-6070.
68. Taveras A.G., Remiszewski S.W., Doll R.J., Cesarz D., Huang E.C., Kirschmeier P., et al. Ras oncoprotein inhibitors: the discovery of potent, ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex. Bioorg Med Chem 1997, 5:125-133.
69. Taylor S.J., Shalloway D. Cell cycle-dependent activation of Ras. Curr Biol 1996, 6:1621-1627.
70. Tentler J.J., Nallapareddy S., Tan A.C., Spreafico A., Pitts T.M., Morelli M.P., et al. Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer. Mol Cancer Ther 2010, 9:3351-3362.
71. Tidyman W.E., Rauen K.A. The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. Curr Opin Genet Dev 2009, 19:230-236.
72. Vakiani E., Solit D.B. KRAS and BRAF: drug targets and predictive biomarkers. J Pathol 2011, 223:219-229.
73. Vanoni M., Bertini R., Sacco E., Fontanella L., Rieppi M., Colombo S., et al. Characterization and properties of dominant-negative mutants of the ras-specific guanine nucleotide exchange factor CDC25(Mm). J Biol Chem 1999, 274:36656-36662.
74. Vetter I.R., Wittinghofer A. The guanine nucleotide-binding switch in three dimensions. Science 2001, 294:1299-1304.
75. Waldmann H., Karaguni I.M., Carpintero M., Gourzoulidou E., Herrmann C., Brockmann C., et al. Sulindac-derived Ras pathway inhibitors target the Ras-Raf interaction and downstream effectors in the Ras pathway. Angew Chem Int Ed 2004, 43:454-458.
76. Wittinghofer A., Waldmann H. Ras - a molecular switch involved in tumor formation. Angew Chem Int Ed 2000, 39:4192-4214.
77. Wong K.K. Recent developments in anti-cancer agents targeting the Ras/Raf/MEK/ERK pathway. Recent Pat Anticancer Drug Discov 2009, 4:28-35.
78. Zenker M. Genetic and pathogenetic aspects of Noonan syndrome and related disorders. Horm Res 2009, 72(Suppl 2):57-63.
79. Zhang Z., Jiang G., Yang F., Wang J. Knockdown of mutant K-ras expression by adenovirus-mediated siRNA inhibits the in vitro and in vivo growth of lung cancer cells. Cancer Biol Ther 2006, 5:1481-1486.
80. Zheng Y., Quilliam L.A. Activation of the Ras superfamily of small GTPases. Workshop on exchange factors. EMBO Rep 2003, 4:463-468.